A Double Blind Randomised Study of Lapatinib and Placebo in Metastatic TCC of the Urothelium
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Lapatinib ditosylate may stop the growth of tumor cells by blocking some of the
enzymes needed for cell growth. It is not yet known whether lapatinib ditosylate is more
effective than a placebo in killing tumor cells.
PURPOSE: This randomized phase II/III trial is studying how well lapatinib ditosylate works
compared to a placebo in treating patients with stage IV bladder cancer.